<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673215</url>
  </required_header>
  <id_info>
    <org_study_id>3SBio-TPO-106</org_study_id>
    <nct_id>NCT03673215</nct_id>
  </id_info>
  <brief_title>The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment</brief_title>
  <official_title>A Phase Ia Dose-escalation Study to Access the Tolerability，Safety，Pharmacokinetics and Pharmacodynamics of Recombinant Human Thrombopoietin in the Patients With Different Degree of Liver Function Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Sunshine Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Sunshine Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics and&#xD;
      pharmacodynamics of recombinant human thrombopoietin in the patients with different degree of&#xD;
      liver function impairment according Child- Pugh class.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled, dose-escalation phase Ia study to&#xD;
      evaluate the tolerability, safety, pharmacokinetics and pharmacodynamics of recombinant human&#xD;
      thrombopoietin. According Child- Pugh class of liver function impairment and different dose&#xD;
      of recombinant human thrombopoietin, nine arms be designed in this study. Each subject in Arm&#xD;
      A will be only administered recombinant human thrombopoietin. Each subject in Arm B and C&#xD;
      will be randomly assigned to accept either recombinant human thrombopoietin or placebo in 5:1&#xD;
      ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by the collection of adverse events</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>To evaluate the adverse events (incidence, severity, outcome, causality with the investigational drug, etc.).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC[0-24]of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO Pharmacokinetic (PK) Parameter: Area under the concentration-time curve from time zero extrapolated to 24 hours(AUC [0-24]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC [0-t] of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter: Area under the concentration-time curve from time zero to last time of quantifiable concentration(AUC [0-t]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC [0-∞]of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter:&#xD;
area under the concentration-time curve from time zero extrapolated to infinity(AUC [0-∞]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter：Observed maximum plasma concentration(Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter：Time to Cmax (tmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter：Elimination half-life (t1/2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT for rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter：Mean residence time (MRT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kel of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter：Elimination rate constant （Kel）.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter：Apparent volume of distribution（Vd）.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of rhTPO</measure>
    <time_frame>For 9 days</time_frame>
    <description>To assess plasma rhTPO PK Parameter：apparent clearance (CL/F).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of rhTPO</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To evaluate the incidence of anti-rhTPO antibodies and neutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Platelet count (PLT)</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>To evaluate the changing curve of platelet count (PLT) in each arm of subjects</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C1-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C1-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C2-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C2-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C3-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C3-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human thrombopoietin</intervention_name>
    <description>Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A</description>
    <arm_group_label>A</arm_group_label>
    <other_name>rhTPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human thrombopoietin</intervention_name>
    <description>Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.</description>
    <arm_group_label>B1</arm_group_label>
    <other_name>rhTPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.</description>
    <arm_group_label>B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human thrombopoietin</intervention_name>
    <description>Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.</description>
    <arm_group_label>C1-1</arm_group_label>
    <other_name>rhTPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C</description>
    <arm_group_label>C1-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human thrombopoietin</intervention_name>
    <description>Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.</description>
    <arm_group_label>C2-1</arm_group_label>
    <other_name>rhTPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C</description>
    <arm_group_label>C2-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human thrombopoietin</intervention_name>
    <description>Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.</description>
    <arm_group_label>C3-1</arm_group_label>
    <other_name>rhTPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C</description>
    <arm_group_label>C3-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients with cirrhosis caused by chronic liver disease who have been diagnosed by&#xD;
             biopsy/imaging (Child-Pugh class A, B, and C).&#xD;
&#xD;
          -  2. Life expectancy≥3 months.&#xD;
&#xD;
          -  3. Platelet count≤80×109/ L.&#xD;
&#xD;
          -  4. Fertile female subjects with a negative pregnancy test during the screening period&#xD;
             and who agree to take effective contraceptive methods Throughout the study period will&#xD;
             be eligible for this study.&#xD;
&#xD;
          -  5. Voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1 Subjects allergic to any component of investigational drug.&#xD;
&#xD;
          -  2 Subjects with cirrhosis caused by drug-induced liver injury.&#xD;
&#xD;
          -  3 Subjects with history of splenectomy or liver transplantation.&#xD;
&#xD;
          -  4 Liver cirrhosis with serious complications, including: hepatic encephalopathy,&#xD;
             intractable ascites, upper gastrointestinal bleeding, etc.&#xD;
&#xD;
          -  5 Subjects with Liver failure.&#xD;
&#xD;
          -  6 Tthe presence of portal vein thrombosis or tumor thrombus was indicated by doppler&#xD;
             ultrasound or CT or MRI and other imaging examinations within 3 months prior to the&#xD;
             beginning of screening.&#xD;
&#xD;
          -  7 Subjects with history of arterial or venous thromboembolism, or with thromboembolic&#xD;
             disease, or with high risk factors for thrombosis, or with a hereditary tendency to&#xD;
             thrombosis, including Antithrombin III deficiency, etc.&#xD;
&#xD;
          -  8 Subjects with history of any disease other than chronic liver disease and cirrhosis&#xD;
             that may result in decreased platelet count and/or abnormal platelet function,&#xD;
             including aplastic anemia, myelodysplastic syndrome (MDS), bone marrow fibrosis, etc.;&#xD;
&#xD;
          -  9 Subjects with diseases with higher bleeding risk, such as coagulation factor&#xD;
             deficiency or Vascular pseudohemophilia factor deficiency.&#xD;
&#xD;
          -  10 Subjects with severe infections that are not effectively controlled.&#xD;
&#xD;
          -  11 Past or present history with any serious disease except liver disease, including:&#xD;
             angina, severe arrhythmia, myocardial infarction, heart failure, Cerebral hemorrhage,&#xD;
             cerebral infarction, intracranial infection, Renal insufficiency( creatinine clearance&#xD;
             rate ≤50 mL/min )，as well as any other diseases that have been judged by investigator&#xD;
             to be unsuitable for this study.&#xD;
&#xD;
          -  12 Subjects who had undergone trans jugular intrahepatic portal shunt (TIPS);&#xD;
&#xD;
          -  13 Subjects with Anti-HIV positive antibodies or Anti- TPHA positive antibodies.&#xD;
&#xD;
          -  14 Subjects who received any therapy with increased platelet count within the 3 weeks&#xD;
             or platelet transfusion within 2 weeks before randomization.&#xD;
&#xD;
          -  15 No more than 30 days or 5 half-lives after investigational drug treatment for other&#xD;
             studies (whichever is longer).&#xD;
&#xD;
          -  16 Subjects with history of primary liver cancer, or an other malignant tumor.&#xD;
&#xD;
          -  17 patients with WHO≥grade 2 of existing active bleeding, or with history of active&#xD;
             bleeding within 2 weeks before randomization.&#xD;
&#xD;
          -  18 Pregnant or breast-feeding women.&#xD;
&#xD;
          -  19 Women who have a pregnancy plan within 3 months.&#xD;
&#xD;
          -  20 Subjects with history of drug abuse and alcoholism within 6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  21 Subjects who do not have the sufficient ability of understanding，communication and&#xD;
             cooperation leading to failure to ensure compliance with protocol will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quanrui WU, Master</last_name>
    <phone>86 10 84892211</phone>
    <email>wuquanrui@3sbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunqiong Cao, MD</last_name>
    <phone>86 10 84892211</phone>
    <email>caosunqiong@3sbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhua Hu, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Haibin Su, MD</last_name>
      <email>suhaibin302@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jinhua HU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

